

CORRECTION

Open Access



Correction: Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK⁺ T-cell lymphoma

Bhawana George^{1†}, Suraj Konnath George^{1†}, Wenyu Shi^{1,2†}, Abedul Haque¹, Ping Shi³, Ghazaleh Eskandari¹, Magnus Axelson⁴, Olle Larsson⁵, Ahmed O. Kaseb⁶ and Hesham M. Amin^{1,7*}

Correction: Journal of Hematology & Oncology (2019) 12:80

<https://doi.org/10.1186/s13045-019-0768-8>

The original article [1] contains an error in Fig. 4a whereby the figure of one well that belonged to one cell line was used in another cell line.

The corrected image can be viewed ahead.

[†]Bhawana George, Suraj Konnath George and Wenyu Shi contributed equally to this work.

The original article can be found online at <https://doi.org/10.1186/s13045-019-0768-8>.

*Correspondence:

Hesham M. Amin
hamin@mdanderson.org

¹ Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Unit 072, 1515 Holcombe Boulevard, Houston, TX 77030, USA

² Department of Hematology, Affiliated Hospital of the University of Nantong, Jiangsu, China


³ State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, China

⁴ Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden

⁵ Department of Oncology and Pathology, Karolinska Institute, Stockholm, Sweden

⁶ Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

⁷ MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA



Published online: 13 June 2023

Reference

1. George B, George SK, Shi W, et al. Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK⁺ T-cell lymphoma. *J Hematol Oncol.* 2019;12:80. <https://doi.org/10.1186/s13045-019-0768-8>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.